Pascal and Francis Bibliographic Databases

Help

Export

Selection :

Permanent link
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24406858

Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond : Protein kinases in cancer: recent findings

Author
BOLOGNA, M1 ; VICENTINI, C2 ; MUZI, P1 ; PACE, G2 ; ANGELUCCI, A1
[1] Chair of General Pathology, Department of Experimental Medicine, University of L'Aquila Medical School and Science and Technology School, Via Vetoio, Coppito-2, 67100 - L'Aquila, Italy
[2] Chair of Urology Clinic, Department of Health Sciences, University of L'Aquila Medical School and Science and Technology School, Via Vetoio, Coppito-2, 67100 - L'Aquila, Italy
Source

Current medicinal chemistry. 2011, Vol 18, Num 19, pp 2827-2835, 9 p ; ref : 70 ref

ISSN
0929-8673
Scientific domain
Biochemistry, molecular biology, biophysics; Pharmacology drugs
Publisher
Bentham, Oak Park, IL
Publication country
United States
Document type
Article
Language
English
Author keyword
Cancer therapy chemotherapy combination therapy prostate cancer tyrosine kinase inhibitors
Keyword (fr)
Activité biologique Antiangiogénique Anticancéreux Article synthèse Cancer de la prostate Chimiothérapie Dasatinib Essai clinique Facteur angiogène Facteur croissance dérivé thrombocyte Facteur croissance endothélium vasculaire Inhibiteur enzyme Lapatinib Pharmacologie Récepteur facteur croissance épiderme Récepteur facteur croissance Sorafénib Traitement associé Transduction signal Transferases Tumeur de la prostate Tumeur maligne Non-specific protein-tyrosine kinase PDGFR Protein-tyrosine kinases Receptor protein-tyrosine kinase VEGFR Cancer Enzyme Pathologie de l'appareil génital mâle Pathologie de l'appareil urinaire Pathologie de la prostate Traitement
Keyword (en)
Biological activity Antiangiogenic agent Antineoplastic agent Review Prostate cancer Chemotherapy Dasatinib Clinical trial Angiogenic factor Platelet derived growth factor Vascular endothelium growth factor Enzyme inhibitor Lapatinib Pharmacology Epidermal growth factor receptor Growth factor receptor Sorafenib Combined treatment Signal transduction Transferases Prostate tumor Malignant tumor Non-specific protein-tyrosine kinase Receptor protein-tyrosine kinase Cancer Enzyme Male genital diseases Urinary system disease Prostate disease Treatment
Keyword (es)
Actividad biológica Antiangiogenico Anticanceroso Artículo síntesis Cáncer de la próstata Quimioterapia Dasatinib Ensayo clínico Factor angiógeno Factor crecimiento derivado plaqueta Factor crecimiento endotelio vascular Inhibidor enzima Lapatinib Farmacología Receptor del factor de crecimiento epidérmico Receptor factor crecimiento Sorafenib Tratamiento asociado Transducción señal Transferases Tumor prostata Tumor maligno Non-specific protein-tyrosine kinase Receptor protein-tyrosine kinase Cáncer Enzima Aparato genital macho patología Aparato urinario patología Prostata patología Tratamiento
Classification
Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02I Urinary system

Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R01 General aspects

Discipline
Pharmacological treatments
Origin
Inist-CNRS
Database
PASCAL
INIST identifier
24406858

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS

Access to the document

Searching the Web